Oxford Nanopore Technologies plc (ONTTF)
USD 1.61
(-1.08%)
USD 1.61
(-1.08%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 37.33 Million GBP | 95.98% |
| 2022 | 19.04 Million GBP | -14.17% |
| 2021 | 22.19 Million GBP | 2.78% |
| 2020 | 21.59 Million GBP | 26.53% |
| 2019 | 17.06 Million GBP | 79.64% |
| 2018 | 9.5 Million GBP | 0.0% |
| 2017 | 9.5 Million GBP | 0.0% |
| 2016 | - GBP | 0.0% |
| 2015 | - GBP | 0.0% |
| 2014 | - GBP | 0.0% |
| 2013 | - GBP | 0.0% |
| 2012 | - GBP | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | - GBP | 0.0% |
| 2023 Q4 | 37.33 Million GBP | 0.0% |
| 2023 FY | 37.33 Million GBP | 95.98% |
| 2023 Q1 | 17.9 Million GBP | -6.03% |
| 2023 Q2 | 17.9 Million GBP | 0.0% |
| 2023 Q3 | 37.33 Million GBP | 108.56% |
| 2022 Q4 | 19.04 Million GBP | -36.59% |
| 2022 FY | 19.04 Million GBP | -14.17% |
| 2022 Q3 | 30.04 Million GBP | 52.24% |
| 2022 Q2 | 19.73 Million GBP | 0.0% |
| 2022 Q1 | 19.73 Million GBP | -11.09% |
| 2021 Q4 | 22.19 Million GBP | 0.0% |
| 2021 FY | 22.19 Million GBP | 2.78% |
| 2021 Q1 | 21.49 Million GBP | -0.44% |
| 2021 Q2 | 21.49 Million GBP | 0.0% |
| 2021 Q3 | 22.19 Million GBP | 3.24% |
| 2020 Q4 | 21.59 Million GBP | 0.0% |
| 2020 FY | 21.59 Million GBP | 26.53% |
| 2020 Q3 | 21.59 Million GBP | 0.0% |
| 2020 Q1 | - GBP | 0.0% |
| 2019 FY | 17.06 Million GBP | 79.64% |
| 2018 FY | 9.5 Million GBP | 0.0% |
| 2017 FY | 9.5 Million GBP | 0.0% |
| 2016 FY | - GBP | 0.0% |
| 2015 FY | - GBP | 0.0% |
| 2014 FY | - GBP | 0.0% |
| 2013 FY | - GBP | 0.0% |
| 2012 FY | - GBP | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Evofem Biosciences, Inc. | 8000.00 USD | -466562.5% |
| Arch Therapeutics, Inc. | - USD | -Infinity% |
| CSL Limited | 11.23 Billion USD | 99.668% |
| Santhera Pharmaceuticals Holding AG | 1.75 Million USD | -2026.656% |
| Regen BioPharma, Inc. | 149.61 Thousand USD | -24852.879% |
| BioStem Technologies, Inc. | 265.63 Thousand USD | -13954.247% |
| Capstone Therapeutics Corp. | 8.26 Million USD | -351.755% |
| Qrons Inc. | 80 Thousand USD | -46566.25% |
| Nascent Biotech, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 20.31 Million USD | -83.798% |
| Oncotelic Therapeutics, Inc. | 1.89 Million USD | -1866.48% |
| Skye Bioscience, Inc. | 171.23 Thousand USD | -21702.838% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | - USD | -Infinity% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Genscript Biotech Corporation | 287.12 Million USD | 86.998% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| Eiger BioPharmaceuticals, Inc. | - USD | -Infinity% |
| Nanobac Pharmaceuticals, Incorporated | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| SQZ Biotechnologies Company | 20.9 Million USD | -78.55% |
| Intellipharmaceutics International Inc. | - USD | -Infinity% |
| Propanc Biopharma, Inc. | 58.64 Thousand USD | -63562.563% |
| Mesoblast Limited | 100.29 Million USD | 62.777% |
| Marizyme, Inc. | 667.12 Thousand USD | -5496.069% |
| Genus plc | 228.2 Million USD | 83.64% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| Pharming Group N.V. | 166.1 Million USD | 77.524% |
| Therapeutic Solutions International, Inc. | 5512.00 USD | -677204.064% |
| CNBX Pharmaceuticals Inc. | - USD | -Infinity% |
| Nymox Pharmaceutical Corporation | - USD | -Infinity% |
| ContraFect Corporation | 2.21 Million USD | -1589.276% |
| PsyBio Therapeutics Corp. | - USD | -Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.4 Million USD | -2561.066% |
| IMV Inc. | 27.39 Million USD | -36.259% |
| AXIM Biotechnologies, Inc. | 5.42 Million USD | -587.978% |
| MultiCell Technologies, Inc. | 36.43 USD | -102478626.324% |
| ONE Bio Corp. | 592.19 Thousand USD | -6204.142% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 55.61 Million USD | 32.869% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | - USD | -Infinity% |
| Q BioMed Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 2.22 Million USD | -1577.134% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | -2939.253% |
| Biomind Labs Inc. | - USD | -Infinity% |
| American Oriental Bioengineering, Inc. | 554.59 Thousand USD | -6631.64% |
| Provectus Biopharmaceuticals, Inc. | 25.29 Thousand USD | -147467.098% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | - USD | -Infinity% |
| Curative Biotechnology, Inc. | - USD | -Infinity% |
| GB Sciences, Inc. | 322 Thousand USD | -11494.099% |
| Alpha Cognition Inc. | - USD | -Infinity% |
| HST Global, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Halberd Corporation | 150 Thousand USD | -24788.667% |
| Enzolytics Inc. | - USD | -Infinity% |
| Agentix Corp. | - USD | -Infinity% |
| Resverlogix Corp. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 164.2 Thousand USD | -22635.605% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 15.35 Million USD | -143.148% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 4456.00 USD | -837714.183% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 126.3 Thousand USD | -29458.518% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -16181.93% |
| Cotinga Pharmaceuticals Inc. | - USD | -Infinity% |
| Kadimastem Ltd | 229.69 Thousand USD | -16153.575% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 1064.00 USD | -3508640.602% |
| LadRx Corporation | - USD | -Infinity% |
| Cell Source, Inc. | - USD | -Infinity% |
| Regen BioPharma, Inc. | 149.61 Thousand USD | -24852.879% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Affymax, Inc. | - USD | -Infinity% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| CytoDyn Inc. | 141 Thousand USD | -26377.305% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | -377.407% |
| SYBLEU INC | 300 Thousand USD | -12344.333% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 369.04 Thousand USD | -10016.001% |
| International Stem Cell Corporation | 445 Thousand USD | -8289.438% |
| Bioxytran, Inc. | - USD | -Infinity% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.15 Million USD | -358.074% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | 457 Thousand USD | -8069.147% |
| Neutra Corp. | - USD | -Infinity% |
| Windtree Therapeutics, Inc. | 1.16 Million USD | -3115.59% |
| PureTech Health plc | 18.25 Million USD | -104.564% |
| Coeptis Therapeutics, Inc. | 150 Thousand USD | -24788.667% |
| IXICO plc | 275 Thousand USD | -13475.636% |
| IntelGenx Technologies Corp. | 11.83 Million USD | -215.339% |
| Gelesis Holdings, Inc. | 26.3 Million USD | -41.902% |
| CSL Limited | 11.23 Billion USD | 99.668% |
| Cellectis S.A. | 36.21 Million USD | -3.098% |